Position in EXEL
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$19,805
+$8,225 QoQ
Shares Held
364
+34.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#648
of 756 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CVA Family Office, LLC holds $743,661 across 48 Biotechnology names. EXEL ranks #6 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
482 | $239,423 | |
| 2 | MRNA |
Moderna, Inc.
|
1,693 | $118,560 | |
| 3 | INCY |
Incyte Corp
|
892 | $101,117 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
143 | $89,166 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
96 | $28,898 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
364 | $19,805 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
81 | $19,518 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
472 | $16,704 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,805 | 364 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $11,580 | 270 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $1,008 | 23 | Shares | Sole | 2026-01-12 | |
| 2025-09-30 | $949 | 23 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $1,013 | 23 | Shares | Sole | 2025-07-31 | |
| 2025-03-31 | $849 | 23 | Shares | Sole | 2025-04-16 | |
| 2024-12-31 | $765 | 23 | Shares | Sole | 2025-01-07 | |
| 2024-09-30 | $596 | 23 | Shares | Sole | 2024-10-10 | |
| 2024-06-30 | $516 | 23 | Shares | Sole | 2024-07-10 | |
| No filing history on record for this holder in this stock. | ||||||